Tokai Pharmaceuticals Inc Stock Nasdaq
Equities
US88907J1079
Biotechnology & Medical Research
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.12M |
---|---|---|---|---|---|
Net income 2024 * | -53M | Net income 2025 * | -74M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.42
x | P/E ratio 2025 * |
-2.29
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.57% |
Latest transcript on Tokai Pharmaceuticals Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 20-04-30 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 21-03-14 |
Steven N. Perrin
PSD | President | 59 | 20-09-13 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 17-04-30 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 20-09-13 |
John S. McBride
BRD | Director/Board Member | 72 | 17-04-30 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |